These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30804224)

  • 1. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
    Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
    Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRN2 is a non-canonical melanoma tumor-suppressor.
    Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
    Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells.
    Ellmann L; Joshi MB; Resink TJ; Bosserhoff AK; Kuphal S
    Lab Invest; 2012 Dec; 92(12):1788-800. PubMed ID: 23069940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
    Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
    Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation.
    Guan J; Zhao Q; Mao W
    Biochim Biophys Acta; 2016 Dec; 1863(12):3106-3115. PubMed ID: 27741411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
    Oing C; Tennstedt P; Simon R; Volquardsen J; Borgmann K; Bokemeyer C; Petersen C; Dikomey E; Rothkamm K; Mansour WY
    Cancer Lett; 2018 Jun; 423():60-70. PubMed ID: 29526801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
    Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
    Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.
    Boyle GM; Woods SL; Bonazzi VF; Stark MS; Hacker E; Aoude LG; Dutton-Regester K; Cook AL; Sturm RA; Hayward NK
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):525-37. PubMed ID: 21435193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
    Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
    Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene.
    Kobi D; Steunou AL; Dembélé D; Legras S; Larue L; Nieto L; Davidson I
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):404-18. PubMed ID: 20337985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells.
    Zang Y; Pascal LE; Zhou Y; Qiu X; Wei L; Ai J; Nelson JB; Zhong M; Xue B; Wang S; Yang D; Lan L; Shan Y; Wang Z
    Cancer Lett; 2018 Feb; 415():198-207. PubMed ID: 29179998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT1 and LSD1 competitively regulate KU70 functions in DNA repair and mutation acquisition in cancer cells.
    Roth M; Wang Z; Chen WY
    Oncotarget; 2016 Aug; 7(31):50195-50214. PubMed ID: 27384990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response.
    Zhang Q; Mady ASA; Ma Y; Ryan C; Lawrence TS; Nikolovska-Coleska Z; Sun Y; Morgan MA
    Nucleic Acids Res; 2019 May; 47(8):4039-4053. PubMed ID: 30722038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating DNA damage response in uveal melanoma through embryonic stem cell microenvironment.
    Zhang Y; Zheng J; Chen M; Zhao S; Ma R; Chen W; Liu J
    BMC Cancer; 2024 Apr; 24(1):519. PubMed ID: 38654216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells.
    Flammiger A; Besch R; Cook AL; Maier T; Sturm RA; Berking C
    J Invest Dermatol; 2009 Apr; 129(4):945-53. PubMed ID: 18923447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
    Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
    EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.
    Simmons JL; Pierce CJ; Al-Ejeh F; Boyle GM
    Sci Rep; 2017 Sep; 7(1):10909. PubMed ID: 28883623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitylation of Ku80 by RNF126 Promotes Completion of Nonhomologous End Joining-Mediated DNA Repair.
    Ishida N; Nakagawa T; Iemura SI; Yasui A; Shima H; Katoh Y; Nagasawa Y; Natsume T; Igarashi K; Nakayama K
    Mol Cell Biol; 2017 Feb; 37(4):. PubMed ID: 27895153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway.
    Lyu F; Huang S; Yan Z; He Q; Liu C; Cheng L; Cong Y; Chen K; Song Y; Xing Y
    Cell Signal; 2024 Jul; 119():111164. PubMed ID: 38583745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.